ORs for severe malaria by Hp genotype
| Groups . | Hp1-1 vs Hp2-1 . | Hp 1-1 vs Hp2-2 . | Hp2-2 vs Hp2-1 . | |||
|---|---|---|---|---|---|---|
| OR (95% CI)* . | P* . | OR (95% CI)† . | P† . | OR (95% CI)* . | P* . | |
| All severe malaria | 1.21 (0.99-1.47) | .06 | 0.89 (0.71-1.12) | .32 | 1.35 (1.1-1.67) | .005 |
| All severe malaria adjusted‡ | 1.24 (1.01-1.53) | .04 | 0.92 (0.72-1.16) | .47 | 1.36 (1.09-1.70) | .007 |
| Severe malaria syndromes‡,§ | ||||||
| Coma | 1.30 (0.99-1.71) | .06 | 1.01 (0.76-1.36) | .90 | 1.33 (1.03-1.70) | .03 |
| Prostration | 1.35 (0.96-1.89) | .09 | 0.90 (0.61-1.33) | .60 | 1.49 (1.04-2.14) | .03 |
| Deep breathing | 1.35 (1.03-1.77) | .03 | 1.0 (0.73-1.36) | .99 | 1.35 (1.01-1.81) | .04 |
| Coma and deep breathing | 1.38 (0.97-1.97) | .08 | 0.91 (0.61-1.35) | .65 | 1.51 (1.04-2.21) | .03 |
| Metabolic acidosis | 1.46 (1.14-1.90) | .003 | 1.03 (0.76-1.36) | .85 | 1.42 (1.08-1.85) | .01 |
| Symptomatic SMA | 1.22 (0.87-1.72) | .25 | 0.90 (0.61-1.33) | .59 | 1.36 (0.95-1.97) | .10 |
| Fatal outcome | 0.71 (0.41-1.23) | .22 | 0.54 (0.30-1.0) | .05 | 1.29 (0.78-2.16) | .32 |
| Groups . | Hp1-1 vs Hp2-1 . | Hp 1-1 vs Hp2-2 . | Hp2-2 vs Hp2-1 . | |||
|---|---|---|---|---|---|---|
| OR (95% CI)* . | P* . | OR (95% CI)† . | P† . | OR (95% CI)* . | P* . | |
| All severe malaria | 1.21 (0.99-1.47) | .06 | 0.89 (0.71-1.12) | .32 | 1.35 (1.1-1.67) | .005 |
| All severe malaria adjusted‡ | 1.24 (1.01-1.53) | .04 | 0.92 (0.72-1.16) | .47 | 1.36 (1.09-1.70) | .007 |
| Severe malaria syndromes‡,§ | ||||||
| Coma | 1.30 (0.99-1.71) | .06 | 1.01 (0.76-1.36) | .90 | 1.33 (1.03-1.70) | .03 |
| Prostration | 1.35 (0.96-1.89) | .09 | 0.90 (0.61-1.33) | .60 | 1.49 (1.04-2.14) | .03 |
| Deep breathing | 1.35 (1.03-1.77) | .03 | 1.0 (0.73-1.36) | .99 | 1.35 (1.01-1.81) | .04 |
| Coma and deep breathing | 1.38 (0.97-1.97) | .08 | 0.91 (0.61-1.35) | .65 | 1.51 (1.04-2.21) | .03 |
| Metabolic acidosis | 1.46 (1.14-1.90) | .003 | 1.03 (0.76-1.36) | .85 | 1.42 (1.08-1.85) | .01 |
| Symptomatic SMA | 1.22 (0.87-1.72) | .25 | 0.90 (0.61-1.33) | .59 | 1.36 (0.95-1.97) | .10 |
| Fatal outcome | 0.71 (0.41-1.23) | .22 | 0.54 (0.30-1.0) | .05 | 1.29 (0.78-2.16) | .32 |
Because children may manifest multiple complications of severe malaria, some subjects contributed data to >1 clinical subgroup.
Compared with Hp2-1 genotype as the reference group, analyzed in a logistic regression model including all genotypes.
Compared with Hp2-2 genotype as the reference group, analyzed in a logistic regression model including all genotypes.
Adjusted for gender, ethnic group, sickle status, and α+thalassemia type.
Defined as in Table 2.